Dynavisc to reduce pain after revision carpal tunnel surgery
Official title: A Multicenter, Evaluator-Blinded, Randomized Evaluation of DYNAVISC in Pain Reduction Following Revision Surgery for Persistent or Recurrent Carpal Tunnel Syndrome
Run by FzioMed · NCT06593977 · Data updated 2026-11-12
This study will test whether applying Dynavisc around the median nerve reduces pain in adults who have persistent or recurrent carpal tunnel symptoms after prior surgery.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | FzioMed Industry-sponsored |
| Locations | 4 sites (Leuven, Belgium and 3 other locations) |
| Status | Recruiting |
| Started | March 26, 2026 |
| Main results expected | August 2029 |
| Study ends | October 2029 |
| Registry record updated | September 2, 2026 |
| Trial ID | NCT06593977 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–65 in generally good health who have recurrent or persistent symptoms in the same hand after prior carpal tunnel release, with at least one positive clinical test (Phalen, Tinel, or monofilament) and ENMG findings consistent with CTS are ideal candidates.
✕Probably not a fit
Patients outside the 18–65 age range, those with other causes of hand pain or severe systemic disease, or those unable to attend follow-up visits are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, multicenter, randomized, evaluator-blinded trial enrolling adults with recurrent or persistent carpal tunnel syndrome after prior release. Participants undergo standard-of-care revision surgery and are randomized to have the median nerve covered with Dynavisc or with a hypothenar fat pad flap, with 25 participants planned per group. Outcomes include patient-reported pain (VAS), hand function (QuickDASH), neuropathic pain (DN4), nerve conduction studies, and grip strength measured at baseline and at 1, 4, and 12 weeks postoperatively. Patients will begin gentle finger and wrist mobilization immediately and resume strenuous activity at six weeks, and assessments are performed by personnel blinded to treatment assignment.
Why it matters
Potential benefit: If successful, Dynavisc could lower postoperative pain and improve nerve recovery and hand function after revision carpal tunnel surgery.
How similar studies have gone: Anti-adhesion and nerve coverage approaches have shown promise in smaller series, but randomized evidence specifically supporting Dynavisc for revision carpal tunnel is limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria * Signed and dated informed consent form; * Stated willingness to comply with all study procedures and availability for the duration of the study; * Aged 18-65 years of age; * In good general health; * Patients experiencing recurrence or persistence of pain in the ipsilateral hand after previous carpal tunnel release for surgical treatment of primary carpal tunnel syndrome; * All of the following physical examination tests must be performed; at least one must be positive: 1. Physical examination demonstrates positive Phalen test; 2. Physical examination demonstrates positive Tinel's test; 3. Physical examination demonstrates positive monofilament test; * ENMG demonstrates median nerve velocity and deviation consistent with the diagnosis of carpal tunnel syndrome. Exclusion criteria * Inability to understand the clinical trial and/or sign the Informed Consent; * Unable or unwilling to attend all of the study prescribed visits and data collection forms; * Active infection requiring medication; * Drug requiring diabetes mellitus; * Collagenopathies; * Hypothyroidism requiring medication; * Rheumatoid arthritis requiring medication; * Autoimmune disease requiring medication; * Cervical nerve compression; * Hematopoietic disorders; * Lacertus fibrosis; * Psychiatric disorder requiring medical treatment; * Subject of workers compensation claim; * History of cancer, except for basal or squamous cell skin cancer; * Known allergic reactions to components of DYNAVISC; * Actively participating in another clinical trial.
Where it's running
-
UZ Leuven
Leuven, Belgium, Belgium Recruiting -
AZ Delta
Roeselare, Belgium, Belgium Recruiting -
Hospital Angelina Caron
Araçatuba, Brazil, Brazil Recruiting -
Azienda Ospedale Universita Padova
Padova, Italy, Italy Recruiting
Study contacts
- Study coordinator: Gere diZerega, MD
- Email: gdizerega@fziomed.com
- Phone: 805-630-2800
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ultrasound-Guided Injection for Carpal Tunnel Syndrome: Hyaluronic Acid vs Corticosteroid vs 5% Glucose
This study tests three ultrasound-guided injections (hyaluronic acid, corticosteroid, and 5% glucose) to see which best helps adults with mild to moderate carpal tunnel syndrome.
-
Open vs ultrasound-guided carpal tunnel release ( CTS )
This study compares two surgical approaches for carpal tunnel syndrome to see which helps people recover better after surgery.
-
Amniotic Membrane and Secretome Added to Carpal Tunnel Release
This trial tests whether adding amniotic membrane and secretome to carpal tunnel surgery helps people with moderate-to-severe CTS recover better than surgery alone.
-
Reliability and validity of hand function tests in carpal tunnel syndrome
This study tests whether three hand function tests (JTHFT, MDT, and Nine-Hole Peg Test) are reliable and valid for people with carpal tunnel syndrome.
-
Neuromobilization, Tendon Gliding, or Both for Mild to Moderate Carpal Tunnel Syndrome
This trial tests whether neuromobilization, tendon gliding exercises, or a combination of both help reduce pain and improve hand function in people with mild to moderate carpal tunnel syndrome.
-
MeDe: Carpal tunnel release with added lacertus release vs carpal tunnel release alone
In adults with carpal tunnel syndrome, this trial tests whether adding a lacertus fibrosus release to the standard carpal tunnel release helps reduce symptoms and improve hand function.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.